News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Half Year 2012 Results and R&D Highlights: DBV Technologies on Track


7/26/2012 9:59:55 AM

BAGNEUX, France--(BUSINESS WIRE)--Regulatory News: The Board of Directors of DBV Technologies (Euronext: DBV – ISIN: FR0010417345), creator of Viaskin®, a new standard in the treatment of allergy, chaired by Pierre-Henri Benhamou met on July 25, 2012 to review the financial statements for the first half 2012, published today. The full interim financial report (regulated information) is available on the Group's website, www.dbv-technologies.com, under the Regulated Information tab in the Investor Relations section. The 2012 half-year financial statements have been subject to a limited review by statutory auditors.

Read at BioSpace.com


comments powered by Disqus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES